Recent single-cell profiling of HR+/HER2− metastatic breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6; encoded by CDK4 and CDK6) inhibitors has revealed distinct TIME patterns correlated with therapeutic response within the framework of targeted therapy. Here, CDK4 is linked to breast cancer.